From CoNFLict to Confidence: Solving a Diagnostic Dilemma Using Neurofilament Light – A Case Report
暂无分享,去创建一个
N. Yassi | R. Watson | D. Eratne | P. Loveland | S. Holper
[1] K. Blennow,et al. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[2] P. Svenningsson,et al. A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.
[3] K. Blennow,et al. Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics , 2021, Molecular neurodegeneration.
[4] Corrigendum. , 2020, Brain : a journal of neurology.
[5] M. DeMarco,et al. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2019, Alzheimer's & dementia.
[6] K. Blennow,et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.
[7] Ludwig Kappos,et al. Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.
[8] L. Schneider,et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. , 2015, JAMA psychiatry.